Sagimet Biosciences (SGMT) Fundamental Analysis: Revenue, Earnings & Valuation

6.25 / 10

Netural

Fundamental measurement shows favorable quality (6.2/10). Constructive metrics: Interest coverage ratio (EBIT / Interest expense) (%) and PB-ROE, but headwinds are noted in Accounts receivable turnover ratio and Fixed assets turnover ratio. Final assessment: positive.

Analysis Checks(7/10)

Revenue-MV

Value-0.18

Score2/3

Weight29.14%

1M Return9.31%

Accounts receivable turnover ratio

Value38.81

Score1/3

Weight-2.64%

1M Return-1.07%

PB-ROE

Value0.50

Score2/3

Weight27.04%

1M Return8.62%

Income tax / Total profit (%)

Value19.89

Score0/3

Weight-4.58%

1M Return-1.92%

Current assets turnover ratio

Value2.32

Score2/3

Weight-1.82%

1M Return-0.73%

Fixed assets turnover ratio

Value8519.45

Score1/3

Weight-3.02%

1M Return-1.26%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.02

Score2/3

Weight-1.82%

1M Return-0.73%

Cost of sales ratio (%)

Value71.88

Score2/3

Weight-2.05%

1M Return-0.84%

Asset-MV

Value-0.72

Score3/3

Weight53.05%

1M Return14.96%

Current ratio

Value22.82

Score3/3

Weight6.71%

1M Return2.55%

Is SGMT fundamentally strong?

SGMT scores 6.25/10 on fundamentals and holds a Fair valuation at present. Backed by its -38.20% ROE, 0.00% net margin, -3.47 P/E ratio, 1.59 P/B ratio, and -8.97% earnings growth, these metrics solidify its Netural investment rating.